NORTHSTAR ASSET MANAGEMENT Co Trims Holdings in Pfizer Inc. $PFE

NORTHSTAR ASSET MANAGEMENT Co cut its holdings in Pfizer Inc. (NYSE:PFE) by 2.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,624 shares of the biopharmaceutical company’s stock after selling 550 shares during the quarter. NORTHSTAR ASSET MANAGEMENT Co’s holdings in Pfizer were worth $451,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer in the 1st quarter worth about $27,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer in the 1st quarter worth about $28,000. North Capital Inc. purchased a new stake in shares of Pfizer in the 1st quarter worth about $28,000. Harbor Asset Planning Inc. purchased a new stake in shares of Pfizer in the 2nd quarter worth about $29,000. Finally, WPG Advisers LLC purchased a new stake in shares of Pfizer in the 1st quarter worth about $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PFE has been the topic of several recent analyst reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Morgan Stanley cut their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Bank of America increased their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Finally, Citigroup increased their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $28.13.

Pfizer Price Performance

NYSE PFE opened at $24.79 on Friday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $29.17. The stock has a market cap of $140.92 billion, a price-to-earnings ratio of 13.18, a PEG ratio of 0.82 and a beta of 0.55. The company’s 50 day moving average is $24.87 and its two-hundred day moving average is $24.17. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the firm posted $0.60 EPS. The company’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.